Sign in

    Elyse Shapiro

    Healthcare Analyst at Canaccord Genuity Group

    Elyse Shapiro is a Healthcare Analyst at Canaccord Genuity Australia, specializing in research on ASX-listed biotechnology and medical companies in the healthcare sector. She actively covers key firms such as Immutep and Mesoblast Limited, regularly issuing buy ratings and detailed price targets reflecting positive performance expectations. Elyse's career with Canaccord Genuity focuses on the Australian healthcare landscape, where she is recognized for her analytical rigor and insights into emerging life sciences opportunities. She holds professional credentials necessary to provide equity research in Australia and is featured as part of Canaccord's global healthcare team.

    Elyse Shapiro's questions to MESOBLAST (MESO) leadership

    Elyse Shapiro's questions to MESOBLAST (MESO) leadership • FY 2025

    Question

    Elyse Shapiro of Canaccord Genuity Group sought more details from the recent FDA meeting regarding the adult GVHD trial, inquired about timelines for the inflammatory bowel disease (IBD) program, and asked if RYONCIL sales could include off-label use.

    Answer

    CEO Silviu Itescu confirmed alignment with the FDA to study RYONCIL in combination with Jakafi for severe adult GVHD. For IBD, he stated a key opinion leader group is finalizing a trial design for medically refractory colitis, with an update expected this quarter. He acknowledged that while they cannot track off-label use by individual physicians, the product is predominantly used for its approved pediatric GVHD indication, supplemented by a formal compassionate use program for adults.

    Ask Fintool Equity Research AI